ASX Announcements

Fundamentals strong as Neuren advances neuroscience pipeline
Preliminary Final Report and statutory accounts
NNZ-2591 positive effects in Phelan-McDermid syndrome model
Plans for Phase 3 trial in Rett syndrome
Neuren retains ex-North America, appoints investment bank
Appendix 4C - quarterly
Final Director's Interest Notice
Ceasing to be a substantial holder
2018 Year-end Business Update
Larry Glass to retire as a director and continue as CSO